- Opthea (OPT) enters into a trading halt ahead of a capital raise
- There is currently no details on how much the company is aiming to raise however did mention of an upcoming funding agreement
- Under the halt, company shares will be paused until Monday, August 15, or when further information has been released to the market
- Shares in Opthea halted at $1.39 on August 11
Opthea (OPT) has entered into a trading halt ahead of a capital raise.
There is currently no details on how much the company is aiming to raise however did mention of an upcoming funding agreement.
Under the halt, company shares will be paused until Monday, August 15, or when further information has been released to the market.
The biotechnology company is developing OPT-302, a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema.
In May, the company presented its clinical data at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.
The ARVO poster presented results of an analysis of subjects with Polypoidal Choroidal Vasculopathy enrolled in the Phase 2b randomised, sham-controlled study of patients with treatment naïve exudative AMD.
Shares in Opthea halted at $1.39 on August 11.